What are the recognized clinical stages of cardiogenic shock?

Stages of Cardiogenic Shock

Cardiogenic shock is classified into five distinct stages (A through E) according to the Society for Cardiovascular Angiography and Interventions (SCAI) classification system, which progresses from at-risk patients to those in extremis, with mortality ranging from approximately 16% in Stage C to 100% in Stage E. 1

SCAI Classification System

The SCAI staging system, endorsed by the American College of Cardiology, American Heart Association, Society of Critical Care Medicine, and Society of Thoracic Surgeons, provides a structured framework for risk stratification 1:

Stage A: At Risk

• Patients who have not yet developed shock but are at risk 1
• No hypoperfusion present 1
• Mortality in this stage is minimal when properly managed 2

Stage B: Beginning Shock

• Early signs of shock without hypoperfusion 1
• Patients may have relative hypotension or tachycardia 1
• In-hospital mortality approximately 18% 3
• Critical distinction: hypoperfusion is absent, which differentiates this from Stage C 1

Stage C: Classic Cardiogenic Shock

• Hypoperfusion is now present, marking the key transition from Stage B 1
• Characterized by hypotension (systolic BP <90 mm Hg or need for vasopressors) plus signs of organ hypoperfusion 4
• Hypoperfusion indicators include: elevated lactate (>2.0 mmol/L), altered mental status, oliguria (<30 mL/h), elevated liver enzymes, and renal dysfunction 4, 5
• In-hospital mortality ranges from 15.8% to 32% 2, 3
• Represents relatively lower risk compared to later stages 2

Stage D: Deteriorating

• Initial interventions have failed to restore stability after at least 30 minutes of observation 1
• Requires escalation of pharmacological support or mechanical circulatory support 1
• In-hospital mortality approximately 63% 3
• Indicates need for aggressive treatment escalation 1

Stage E: Extremis

• Patient in cardiovascular collapse, often with circulatory arrest 1
• Highly unstable with refractory shock despite maximal support 1
• In-hospital mortality approaches 100% 3
• May require immediate mechanical circulatory support or consideration for advanced therapies 1

Clinical Application and Prognostic Value

Dynamic Staging Assessment

• The SCAI stage at 24 hours after admission is a stronger predictor of mortality than admission staging 3
• Reclassification at 24 hours improves risk stratification and identifies patients requiring treatment escalation 3
• Lower baseline stage is associated with higher incidence of stage escalation and shorter time to reach maximum stage 5
• Both baseline and maximum SCAI stage during hospitalization are independent predictors of in-hospital mortality 5

Defining Criteria for Staging

The Cardiogenic Shock Working Group has validated specific parameters that define each stage 5:

• Systolic blood pressure - progressively lower with advancing stages 5
• Lactate level - marker of tissue hypoperfusion, increases with severity 5
• Alanine transaminase (ALT) - reflects hepatic hypoperfusion 5
• Systemic pH - worsens with metabolic acidosis in advanced stages 5
• Treatment intensity - number and type of vasoactive drugs and mechanical support devices 5

Important Caveats

The 2022 SCAI revision emphasizes that cardiogenic shock should be viewed as a continuum rather than discrete categories, incorporating phenotypic elements and dynamic progression 4. The American Heart Association notes that definitions based solely on hypotension are inadequate - patients with isolated hypoperfusion (elevated lactate and creatinine) without hypotension have 17.2% mortality, while combined hypotension/hypoperfusion carries 34% mortality 4.

Older adults (>70 years) have higher SCAI stages at presentation and different phenotypic profiles, often presenting with the cardiorenal phenotype characterized by greater congestion and comorbidity burden 4. This population requires special consideration as chronological age alone should not determine treatment decisions 4.

Clinical Utility

The SCAI staging system outperforms traditional scoring systems (Sequential Organ Failure Assessment and IABP-SHOCK II scores) in predicting mortality 2. This classification facilitates:

• Standardized communication among multidisciplinary shock teams 1
• Treatment escalation decisions - particularly identifying when initial therapies have failed (Stage D) 1
• Patient selection for mechanical circulatory support and advanced therapies 2
• Prognostication for clinical decision-making and family discussions 2

The system is applicable across the entire care spectrum from pre-hospital providers to intensive care settings 1, though it requires ongoing validation studies to refine its prognostic implications 1.